Octave provides precision care solutions for multiple sclerosis (MS) and other conditions. The company focuses on using data to generate insights for healthcare.

Octave

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave  is currently collaborating with leading clinics, payers, and pharma companies across the country.


Michael J. Fox Foundation

Echo Health Ventures

Section 32 BlueCross BlueShield Venture Partners

Northpond Ventures

Deerfield

Casdin Capital

The Blue Venture Fund

Merck Global Health Innovation Fund

Hikma Ventures

Intermountain Ventures

🚀 Exciting News! 🚀

We are thrilled to share that Octave has been invited to participate in the Multiple Sclerosis and Neuroimmune Summit 2.0 hosted by Dr. Terry Wahls MD and presented by DrTalks.com 🥼

📅 Dates: August 20th - August 26th

We are incredibly honored to be part of this influential event and look forward to connecting with industry leaders and innovators. Catch our presentation titled "Track MS Progress: Key Biomarkers Explained"—a deep dive into how Octave’s Multiple Sclerosis Disease Activity (MSDA) Test is used in establishing a baseline and improving longitudinal clinical management in MS care.

💡Claim your free spot to join the Summit to learn from 40+ world-leading experts: https://lnkd.in/gkyDhvwa 

#DrTalks #Innovation #Biomarkers #Octave #PrecisionMedicine

We are thrilled to announce the newest addition to our leadership team at Octave — please join us in welcoming Marcel Konrad, CPA as our new Chief Financial Officer!

With a distinguished career in financial strategy and corporate leadership, Marcel brings a wealth of experience and a proven track record of driving financial excellence and strategic growth. 

In his new role at Octave, Marcel will lead our financial strategy, enhance our operational efficiency, and drive our commitment to delivering exceptional value to our stakeholders. We are confident that his expertise and vision will be instrumental in shaping our growth and allow us to continue delivering our #PrecisionCareSolution to more patients. 

Read more here: https://lnkd.in/gY-FySyH

#Welcome #Octave #Neurodegenerativedisease

Thank you Ferhan Qureshi for representing Octave at the #Olinkbiomarkersummit and presenting "The Octave MSDA test product journey: Improving insights for patients with MS utilizing a clinically validated assay developed on the Olink Proteomics platform."
#Olink #biomarker #precisionmedicine

Go check out Stephen Krieger and Kelly Leyden at American Academy of Neurology Wednesday 4/17 @ the 5:30 pm - 6:30 pm poster session. One of the coolest projects I’ve ever been a part of…bringing the topographical model into the 3D brain space. You will NOT be disappointed. #brain #3D #multiplesclerosis #medicaleducation #scicomm 🧠🧪 Octave 

https://lnkd.in/eTpWmzYC

A peek at some of the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) posters we'll be sharing tonight from 6-7:30.  https://lnkd.in/eNEt66Ad for all titles. 
#multiplesclerosis #precisioncare

Thank you Critical Path Institute (C-Path), we look forward to our partnership.

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

HSTS

CEO & Co-Founder

Sandeep Acharya

Sejal Shah

VP of Marketing

Annie Winship

VP Clinical Care

Golee Abrishami, Ph.D.

VP Product

Kathleen Mullaney

Vice President - Support

Stephen Mann

Director of Program Management

David Reed

Senior Clinical Director

Dianne Mani

Engineering Manager

Emilie Hester

Clinic Director, Bryant Park

Erica Hamilton

Nan Li

Bharat Mediratta

Vice President of Support

Bailey Stoner

Software Engineer

Western US Companies With More Than $1M in Revenue (Top 10K)

California Health Care Companies (Top 10K)

West Coast Health Care Companies (Top 10K)

Wellness Companies With More Than 100 Employees

Octave provides mental health care that’s both accessible to people and sustainable for providers. It partners with clients to develop personalized care plans to best suit the individual's needs. Grounded in science, Octave enables clients to experience profound change that is just as measurable as it is meaningful.

Venture Round - Octave

Avidity Partners

Cigna Ventures

Novo Holdings

Series C - Octave

Health Velocity Capital

Series B - Octave

Greycroft

Series A - Octave

Non Equity Assistance - Octave

Felicis

Seed Round - Octave

Computer and Software Services and Scientific Services

San Francisco

California

United States

North America

Octave Expands Mental Health Services to 10 New States

Octave® Bioscience, Inc. Announces Publication in Nature Communications

Octave Welcomes Two Seasoned Healthcare Leaders to Its Board

Chutes & Ladders—Octave names quartet of leaders

Octave® Bioscience, Inc. Presents Data Highlighting Application and Impact of its Precision Care Solution at MSMilan2023

FOUNDER OF OCTAVE INSTITUTE, CHAVALIT FREDERICK TSAO MAKES A COLLABORATIVE CONTRIBUTION TOWARDS HALOGEN FOUNDATION

Octave Bioscience: Precision Care Company Extends $30 Million Series B Funding Round

Octave Bioscience Closes $30M Extension to Series B Funding

Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases

news impact assignment basic	general
public peers	general	Aug 25, 2024 8:36 AM	3b0aca04
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 29, 2024 5:10 PM	a28c649d
crunchbase profile	general	Oct 30, 2024 9:12 AM	1c943e4a
li profile	general	Aug 25, 2024 8:36 AM	cfa02340
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	74117be9
peers	general	Aug 25, 2024 8:36 AM	fd9d2983
news basic	general	Aug 25, 2024 8:36 AM	467fda76
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:OCTAVEBIO

Octave